Director dealings: Astrazeneca CEO raises stake
18th Sep 2026 14:14
(Sharecast News) - Astrazeneca revealed on Friday that chief executive Pascal Soriot had acquired 60,000 ordinary shares in the FTSE 100-listed drugmaker.
Read moreDeutsche Bank upgrades Astrazeneca to 'hold'
15th Sep 2026 12:42
(Sharecast News) - Deutsche Bank upgraded Astrazeneca from 'sell' to 'hold' on Tuesday and nudged its price target up from 11,500p to 11,700p, saying the risk‑reward scenario had shifted following last week's negative SERENA-4 readout and a period of underperformance against European large‑cap peers.
Read moreAstrazeneca's Etcamah trial fails to meet primary endpoint
14th Sep 2026 08:47
(Sharecast News) - Drugmaker Astrazeneca said on Monday that its SERENA‑4 Phase III trial of breast cancer treatment Etcamah (camizestrant) in combination with palbociclib did not meet its primary endpoint, although a numerical improvement in progression‑free survival was observed, as the company reaffirmed confidence in the drug's broader development programme.
Read moreAstraZeneca sees positive results from lung cancer drug trial
8th Sep 2026 15:18
(Sharecast News) - AstraZeneca said on Tuesday that a clinical trial studying its Imfinzi treatment showed positive results in patients with extensive-stage small-cell lung cancer (ES-SCLC).
Read moreAstraZeneca's breast cancer drug granted accelerated approval in the US
7th Sep 2026 07:10
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer drug Etcamah (camizestrant), used alongside a CDK4/6 inhibitor, has been granted accelerated approval in the US for patients with a common form of advanced breast cancer who show signs of developing resistance to standard hormone therapy.
Read moreAstraZeneca lifts lung‑cancer pipeline with Zegfrovy deal, Tagrisso data
1st Sep 2026 07:38
(Sharecast News) - Drugmaker Astrazeneca delivered a pair of lung‑cancer updates on Tuesday, with the group completing a global licensing deal for Zegfrovy (sunvozertinib) while also reporting positive Phase III data for a Tagrisso-Orpathys combination in first‑line MET‑overexpressing EGFR‑mutated disease.
Read moreAstrazeneca's Tezspire delivers positive results in EoE trial
27th Aug 2026 07:14
(Sharecast News) - Drugmaker AstraZeneca said on Thursday that Tezspire had delivered positive Phase III results in eosinophilic oesophagitis (EoE), hitting both co‑primary endpoints and all key secondary measures, with improvements sustained through 52 weeks.
Read moreAstraZeneca posts mixed lung‑cancer trial updates
17th Aug 2026 07:16
(Sharecast News) - Drugmaker AstraZeneca posted two contrasting lung‑cancer updates on Monday, discontinuing one Phase III study while reporting strong survival gains from another.
Read moreAstraZeneca, Bristol Myers Squibb in talks over $400bn tie-up - report
3rd Aug 2026 08:15
(Sharecast News) - AstraZeneca is reportedly in talks to combine with US rival Bristol Myers Squibb in a deal that would create one of the world's biggest pharmaceutical groups, valued at nearly $400bn.
Read moreAstraZeneca reports first-half growth, disappointment in Ultomiris trial
27th Jul 2026 09:10
(Sharecast News) - AstraZeneca reported first-half total revenue of $30.7bn on Monday, up 9%, while core earnings per share increased 12% to $5.21 as double-digit growth in its Oncology and Rare Disease businesses offset headwinds from Farxiga's US loss of exclusivity and China's volume-based procurement programme.
Read moreAstraZeneca breast cancer drug receives EU approval
23rd Jul 2026 12:28
(Sharecast News) - A breast cancer drug developed by AstraZeneca has been approved in the European Union for the treatment of certain types of the disease, the pharmaceutical giant announced on Thursday.
Read moreAstraZeneca shares slide on failure of cardiomyopathy trial
9th Jul 2026 09:57
(Sharecast News) - AstraZeneca said on Thursday that the phase 3 CARDIO-TTRansform trial of Wainua in adults with transthyretin-mediated amyloid cardiomyopathy did not meet its primary endpoint, failing to show a statistically significant benefit against placebo on the composite measure of cardiovascular mortality and recurrent cardiovascular clinical events up to 140 weeks.
Read moreAstraZeneca's Datroway and Enhertu candidates receive EU approval
29th Jun 2026 07:07
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer therapy Datroway has been recommended for approval in the EU as a first‑line monotherapy for adults with unresectable or metastatic triple‑negative breast cancer who are not eligible for PD‑1/PD‑L1 inhibitor treatment.
Read moreAstrazeneca's Imfinzi receives green light from US FDA
29th May 2026 07:21
(Sharecast News) - Drugmaker Astrazeneca said on Friday that Imfinzi has been approved in the US as part of the first immunotherapy‑based combination for patients with high‑risk, non‑muscle‑invasive bladder cancer who have not previously been treated with Bacillus Calmette-Guérin.
Read moreUS FDA pushes back decision on Astrazeneca's camizestrant
27th May 2026 09:01
(Sharecast News) - Drugmaker Astrazeneca said the US Food and Drug Administration had pushed back its decision on camizestrant after requesting additional data for the drug's new application.
Read more